MX2025006722A - Compuesto de 2-azabiciclo[3.1.1]heptano - Google Patents
Compuesto de 2-azabiciclo[3.1.1]heptanoInfo
- Publication number
- MX2025006722A MX2025006722A MX2025006722A MX2025006722A MX2025006722A MX 2025006722 A MX2025006722 A MX 2025006722A MX 2025006722 A MX2025006722 A MX 2025006722A MX 2025006722 A MX2025006722 A MX 2025006722A MX 2025006722 A MX2025006722 A MX 2025006722A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- azabiciclo
- orexin
- receptors
- heptane compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022201488 | 2022-12-16 | ||
| PCT/JP2023/044987 WO2024128305A1 (ja) | 2022-12-16 | 2023-12-15 | 2-アザビシクロ[3.1.1]ヘプタン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025006722A true MX2025006722A (es) | 2025-07-01 |
Family
ID=91485946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025006722A MX2025006722A (es) | 2022-12-16 | 2025-06-09 | Compuesto de 2-azabiciclo[3.1.1]heptano |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4635944A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024128305A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250112793A (cg-RX-API-DMAC7.html) |
| CN (1) | CN120603816A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023395547A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025006722A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202430169A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024128305A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260012686A (ko) * | 2024-07-18 | 2026-01-27 | (주)셀트리온 | 신규한 오렉신 2 수용체 작용제 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015056100A2 (en) | 2013-10-14 | 2015-04-23 | Marvell World Trade Ltd. | Systems and methods for graphics process units power management |
| SG11201604639YA (en) | 2013-12-12 | 2016-07-28 | Univ Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| JP6359924B2 (ja) | 2014-09-17 | 2018-07-18 | トヨタ自動車株式会社 | 非接触送受電システム |
| SG11201806429PA (en) | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| US10428023B2 (en) * | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| CA3074059A1 (en) * | 2017-09-01 | 2019-03-07 | Chronos Therapeutics Limited | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
| WO2019081939A1 (en) * | 2017-10-25 | 2019-05-02 | Chronos Therapeutics Limited | 2-AZABICYCLO [3.1.1] DERIVATIVES AS ANTAGONISTS OF OREXIN-1 AND OREXIN-2 RECEPTORS |
| PE20211700A1 (es) * | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| PE20221730A1 (es) | 2019-11-27 | 2022-11-07 | Sumitomo Pharma Co Ltd | Derivado de cicloalquilurea |
| CN119235864A (zh) | 2020-07-17 | 2025-01-03 | 卫材R&D管理有限公司 | 取代的哌啶化合物及其用途 |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| CN116969888A (zh) * | 2022-04-24 | 2023-10-31 | 优领医药科技(上海)有限公司 | 含环丙基并环类衍生物、其药学上可接受的盐及其制备方法和应用 |
-
2023
- 2023-12-15 JP JP2024564440A patent/JPWO2024128305A1/ja active Pending
- 2023-12-15 KR KR1020257019334A patent/KR20250112793A/ko active Pending
- 2023-12-15 AU AU2023395547A patent/AU2023395547A1/en active Pending
- 2023-12-15 CN CN202380092851.0A patent/CN120603816A/zh active Pending
- 2023-12-15 TW TW112149084A patent/TW202430169A/zh unknown
- 2023-12-15 EP EP23903586.8A patent/EP4635944A1/en active Pending
- 2023-12-15 WO PCT/JP2023/044987 patent/WO2024128305A1/ja not_active Ceased
-
2025
- 2025-06-09 MX MX2025006722A patent/MX2025006722A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120603816A (zh) | 2025-09-05 |
| JPWO2024128305A1 (cg-RX-API-DMAC7.html) | 2024-06-20 |
| EP4635944A1 (en) | 2025-10-22 |
| WO2024128305A1 (ja) | 2024-06-20 |
| AU2023395547A1 (en) | 2025-06-26 |
| KR20250112793A (ko) | 2025-07-24 |
| TW202430169A (zh) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211700A1 (es) | Compuesto heterociclico y su uso | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| EA200401167A1 (ru) | Производные тропана в качестве модуляторов ccr5 | |
| EP4699609A3 (en) | Heterocyclic glp-1 agonists | |
| MA32231B1 (fr) | Composés organiques | |
| PL1755590T3 (pl) | Kombinacja glikopirolanu i agonisty receptora adrenergicznego beta 2 | |
| EA200200769A1 (ru) | Ингибиторы гиразы и их применение | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| EA200500354A1 (ru) | Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| MX2025007434A (es) | Compuesto con anillo fusionado de pirazol, metodo de preparacion y uso del mismo | |
| EE9900217A (et) | Sulfiinhappe derivaadid, nende valmistamine ja kasutamine | |
| JOP20240059A1 (ar) | المركبات المثبطة إيميدازوبيريدازين il-17 | |
| MX2023010125A (es) | Inhibidores del sarcomero cardiaco. | |
| MX2023012004A (es) | DERIVADO DEL ÁCIDO BÓRICO QUE ACTÚA COMO INHIBIDOR DE LA ß-LACTAMASA. | |
| MX2025001749A (es) | Compuesto como inhibidor del canal de sodio dependiente del voltaje | |
| MX385971B (es) | Compuesto de griseofulvina. | |
| MX2025000174A (es) | Compuestos y metodos terapeuticos. | |
| EP4643954A3 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| BR112023006312A2 (pt) | Composto, métodos para preparar o composto, composição farmacêutica e uso do composto | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| WO2023199091A8 (en) | Heterocyclic compound | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2023015408A (es) | Inhibidores de transglutaminasas. |